Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SERA - US81749D1072 - Common Stock

3.32 USD
-0.08 (-2.35%)
Last: 11/26/2025, 8:03:13 PM
Fundamental Rating

3

SERA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While SERA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SERA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SERA has reported negative net income.
SERA had a negative operating cash flow in the past year.
SERA had negative earnings in each of the past 5 years.
In the past 5 years SERA always reported negative operating cash flow.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -29.27%, SERA is in the better half of the industry, outperforming 67.73% of the companies in the same industry.
With a decent Return On Equity value of -37.10%, SERA is doing good in the industry, outperforming 73.36% of the companies in the same industry.
Industry RankSector Rank
ROA -29.27%
ROE -37.1%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SERA has more shares outstanding
SERA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SERA has been reduced compared to a year ago.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

SERA has an Altman-Z score of -1.40. This is a bad value and indicates that SERA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SERA (-1.40) is comparable to the rest of the industry.
There is no outstanding debt for SERA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.4
ROIC/WACCN/A
WACC8.64%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.73 indicates that SERA should not have too much problems paying its short term obligations.
The Current ratio of SERA (1.73) is worse than 79.92% of its industry peers.
A Quick Ratio of 1.73 indicates that SERA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.73, SERA is doing worse than 78.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.73
Quick Ratio 1.73
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.22% over the past year.
Looking at the last year, SERA shows a very negative growth in Revenue. The Revenue has decreased by -74.84% in the last year.
SERA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.00% yearly.
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-74.84%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-44.83%

3.2 Future

SERA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.82% yearly.
SERA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 195.78% yearly.
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SERA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

SERA's earnings are expected to grow with 14.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.96%
EPS Next 3Y14.08%

More info and screens

0

5. Dividend

5.1 Amount

SERA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERA PROGNOSTICS INC-A

NASDAQ:SERA (11/26/2025, 8:03:13 PM)

3.32

-0.08 (-2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-17 2026-03-17/amc
Inst Owners64.87%
Inst Owner Change-2.64%
Ins Owners2.66%
Ins Owner Change2.01%
Market Cap126.36M
Revenue(TTM)77.00K
Net Income(TTM)-32.73M
Analysts85
Price TargetN/A
Short Float %1.46%
Short Ratio9.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.52%
Min EPS beat(2)14.75%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)8.99%
Min EPS beat(4)-6.95%
Max EPS beat(4)30.28%
EPS beat(8)6
Avg EPS beat(8)11.42%
EPS beat(12)10
Avg EPS beat(12)13.93%
EPS beat(16)11
Avg EPS beat(16)5.03%
Revenue beat(2)0
Avg Revenue beat(2)-63.9%
Min Revenue beat(2)-74.36%
Max Revenue beat(2)-53.43%
Revenue beat(4)1
Avg Revenue beat(4)-34.37%
Min Revenue beat(4)-74.36%
Max Revenue beat(4)56.86%
Revenue beat(8)1
Avg Revenue beat(8)-48.2%
Revenue beat(12)3
Avg Revenue beat(12)-35.67%
Revenue beat(16)3
Avg Revenue beat(16)-38.4%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1169.99
P/FCF N/A
P/OCF N/A
P/B 1.43
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.32
TBVpS2.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -29.27%
ROE -37.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.79%
Cap/Sales 615.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.73
Quick Ratio 1.73
Altman-Z -1.4
F-Score3
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)83.45%
Cap/Depr(5y)92.8%
Cap/Sales(3y)588.1%
Cap/Sales(5y)777.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y21.7%
EPS Next 2Y7.96%
EPS Next 3Y14.08%
EPS Next 5Y8.82%
Revenue 1Y (TTM)-74.84%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-44.83%
Revenue Next Year118.18%
Revenue Next 2Y255.5%
Revenue Next 3Y236.73%
Revenue Next 5Y195.78%
EBIT growth 1Y-4.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.86%
OCF growth 3YN/A
OCF growth 5YN/A

SERA PROGNOSTICS INC-A / SERA FAQ

What is the fundamental rating for SERA stock?

ChartMill assigns a fundamental rating of 3 / 10 to SERA.


Can you provide the valuation status for SERA PROGNOSTICS INC-A?

ChartMill assigns a valuation rating of 0 / 10 to SERA PROGNOSTICS INC-A (SERA). This can be considered as Overvalued.


Can you provide the profitability details for SERA PROGNOSTICS INC-A?

SERA PROGNOSTICS INC-A (SERA) has a profitability rating of 1 / 10.


What is the financial health of SERA PROGNOSTICS INC-A (SERA) stock?

The financial health rating of SERA PROGNOSTICS INC-A (SERA) is 5 / 10.


What is the expected EPS growth for SERA PROGNOSTICS INC-A (SERA) stock?

The Earnings per Share (EPS) of SERA PROGNOSTICS INC-A (SERA) is expected to grow by 21.7% in the next year.